• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Satsuma Pharmaceuticals registers $75m IPO

September 9, 2019 By Nancy Crotti

Satsuma Pharmaceuticalssatsuma-pharmaceuticals has registered an initial public offering, seeking to raise $75 million, according to a regulatory filing.

The South San Francisco-based company is working on STS101, a nasal powder version of dihydroergotamine for migraine. It intends to use the money to fund its Phase 3 safety and efficacy clinical trials for STS101, manufacturing costs, preparation for the product’s commercial launch and for working capital and general corporate purposes.

The powdered version of the drug would be self-administered using a proprietary pre-filled, single-use, nasal delivery device.

Satsuma is offering 5 million shares of its common stock at a range of range at $14 to $16 per share and has applied to list its common stock on The Nasdaq Global Market under the symbol “STSA.” Credit Suisse, SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering.

Satsuma expects to grant the offerings’ underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

In April, the company raised $62 million in a Series B preferred stock financing, led by Wellington Management.

Satsuma said it began the Phase 3 efficacy trial in July and expects to report topline data in the second half of 2020.

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Pain Management, Uncategorized, Wall Street Beat Tagged With: satsumapharmaceuticals

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS